Search research articles
Contact Us
Filters
Showing results (261-270 of 279) with videos related to
Page
of 28
Sort By:
The Neurohospitalist
|
April 8, 2016
A Nationwide Analysis of Outcomes of Weekend Admissions for Intracerebral Hemorrhage Shows Disparities Based on Hospital Teaching Status
Achint A Patel, Abhimanyu Mahajan, Alexandre Benjo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 16, 2018
Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial
John J Coen, Peixin Zhang, Philip J Saylor, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 15, 2024
Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer-Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial
John J Coen, Joseph P Rodgers, Philip J Saylor, et al.
European Urology Open Science
|
March 4, 2022
Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer
Benjamin W Fischer-Valuck, Brian C Baumann, Simon A Brown, et al.
Brachytherapy
|
July 7, 2020
Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer
Benjamin W Fischer-Valuck, Yuan James Rao, Randall J Brenneman, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 6, 2021
Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526)
Juanita Crook, Joseph P Rodgers, Thomas M Pisansky, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 3, 2022
Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus <sup>18</sup>F-Fluciclovine PET/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 Trial
Ismaheel O Lawal, Ashesh B Jani, Omotayo A Adediran, et al.
Clinical Nuclear Medicine
|
February 8, 2023
Impact of 18 F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy
Ismaheel O Lawal, Charles Marcus, David M Schuster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 3, 2024
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926
Douglas M Dahl, Joseph P Rodgers, William U Shipley, et al.
Lancet (London, England)
|
May 10, 2021
<sup>18</sup>F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial
Ashesh B Jani, Eduard Schreibmann, Subir Goyal, et al.
Page
of 28
Search research articles
Search
Showing results (261-270 of 279) with videos related to
Sort By:
Page
of 28
The Neurohospitalist
|
April 8, 2016
A Nationwide Analysis of Outcomes of Weekend Admissions for Intracerebral Hemorrhage Shows Disparities Based on Hospital Teaching Status
Achint A Patel, Abhimanyu Mahajan, Alexandre Benjo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 16, 2018
Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial
John J Coen, Peixin Zhang, Philip J Saylor, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 15, 2024
Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer-Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial
John J Coen, Joseph P Rodgers, Philip J Saylor, et al.
European Urology Open Science
|
March 4, 2022
Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer
Benjamin W Fischer-Valuck, Brian C Baumann, Simon A Brown, et al.
Brachytherapy
|
July 7, 2020
Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer
Benjamin W Fischer-Valuck, Yuan James Rao, Randall J Brenneman, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 6, 2021
Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526)
Juanita Crook, Joseph P Rodgers, Thomas M Pisansky, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 3, 2022
Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus <sup>18</sup>F-Fluciclovine PET/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 Trial
Ismaheel O Lawal, Ashesh B Jani, Omotayo A Adediran, et al.
Clinical Nuclear Medicine
|
February 8, 2023
Impact of 18 F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy
Ismaheel O Lawal, Charles Marcus, David M Schuster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 3, 2024
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926
Douglas M Dahl, Joseph P Rodgers, William U Shipley, et al.
Lancet (London, England)
|
May 10, 2021
<sup>18</sup>F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial
Ashesh B Jani, Eduard Schreibmann, Subir Goyal, et al.
Page
of 28